A practical reference on lipolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
=== Atomic === A neptunium atom has 93 electrons, arranged in the configuration [Rn] 5f4 6d1 7s2. This differs from the configuration expected by the Aufbau principle in that one electron is in the 6d subshell instead of being as expected in the 5f subshell. This is because of the similarity of the electron energies of the 5f, 6d, and 7s subshells. In forming compounds and ions, all the valence electrons may be lost, leaving behind an inert core of inner electrons with the electron configuration of the noble gas radon; more commonly, only some of the valence electrons will be lost. The electron configuration for the tripositive ion Np3+ is [Rn] 5f4, with the outermost 7s and 6d electrons lost first: this is exactly analogous to neptunium's lanthanide homolog promethium, and conforms to the trend set by the other actinides with their [Rn] 5fn electron configurations in the tripositive state. The first ionization potential of neptunium was measured to be at most 6.19±0.12 eV in 1974, based on the assumption that the 7s electrons would ionize before 5f and 6d; more recent measurements have refined this to 6.2657 eV.
131I decays with a half-life of 8.0249 days emitting beta particles and gamma rays. Most often (89%), 131I expends its 971 keV of decay energy by transforming to stable xenon-131 in two steps, with gamma decay following rapidly after beta decay:
=== Women's participation === The Sovereignty Council was mostly male, with two of the eleven members being female: Aisha Musa el-Said and Raja Nicola. At a lower level, Siham Osman was nominated Under-Secretary of the Minister of Justice, and acts on behalf of the Minister of Justice with his authorisation when he is on travels. The Sudanese Women's Union argued that women had played as significant a role as men in the political changes of 2019 and that Sudanese women "claim an equal share of 50-50 with men at all levels, measured by qualifications and capabilities".
Sources: en.wikipedia.org
=== Institutional reform === Talarico has proposed institutional reforms including term limits for members of U.S. Congress, banning congressional stock trading, and banning gerrymandering. He supports eliminating the filibuster under the current rules in the U.S. Senate, but supports the talking filibuster. He has advocated for reform of the U.S. Supreme Court including through term limits. He supports an enforceable code of ethics for the court's justices, "for recusals, financial disclosures, and limitations on accepting gifts." He said he is "open" to increasing the number of justices.
=== Classification methods === Classification methods use data to train a program (classifier) to distinguish positive examples of interacting protein/domain pairs with negative examples of non-interacting pairs. Popular classifiers used are Random Forest Decision (RFD) and Support Vector Machines. RFD produces results based on the domain composition of interacting and non-interacting protein pairs. When given a protein pair to classify, RFD first creates a representation of the protein pair in a vector. The vector contains all the domain types used to train RFD, and for each domain type the vector also contains a value of 0, 1, or 2. If the protein pair does not contain a certain domain, then the value for that domain is 0. If one of the proteins of the pair contains the domain, then the value is 1. If both proteins contain the domain, then the value is 2. Using training data, RFD constructs a decision forest, consisting of many decision trees. Each decision tree evaluates several domains, and based on the presence or absence of interactions in these domains, makes a decision as to if the protein pair interacts. The vector representation of the protein pair is evaluated by each tree to determine if they are an interacting pair or a non-interacting pair. The forest tallies up all the input from the trees to come up with a final decision. The strength of this method is that it does not assume that domains interact independent of each other. This makes it so that multiple domains in proteins can be used in the prediction.
== Distribution and habitat == The fool's mushroom grows in European woodlands and hardwood forests in springtime as the fungus' Latin name (Amanita verna or spring destroying angel) suggests. Unlike various closely related poisonous amanitas, this mushroom is not known to occur in North America.
=== Infantile-Onset (IOPD) === The infantile-onset (IOPD) form usually comes to medical attention within the first few months of life, either clinically or through newborn screening. The usual presenting features are cardiomyopathy, cardiomegaly, hypotonia, respiratory distress, muscle weakness, feeding difficulties, and failure to thrive. IOPD patients can be further classified by Cross-Reactive Immunological Material (CRIM) status which is an important predictor of clinical response. Patients that produce no GAA protein are referred to as CRIM negative. Therefore, they can develop highly sustained antibody titers for enzyme replacement therapy (ERT). Immunomodulation or immunotherapy is an effective treatment to prevent an immune response to ERT. The main clinical findings include floppy baby appearance, delayed motor milestones, and feeding difficulties. Moderate hepatomegaly may or may not be present. Facial features include macroglossia, hypernasal speech, hearing loss, and myopathic facies. Cardiopulmonary involvement is manifested by increased respiratory rate, use of accessory muscles for respiration, recurrent chest infections, decreased air entry in the left lower zone (due to cardiomegaly), arrhythmias, and evidence of heart failure. Before the development of a treatment, the median age at death in untreated cases was 8.7 months, usually due to cardiorespiratory failure. However, this outcome has drastically changed since enzyme replacement therapy became available, improving with early initiation of treatment.
Sources: en.wikipedia.org
== Pharmacology == Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not identical, pathways. Its efficacy is believed to result from central dopaminergic and serotonergic antagonism except paliperidone, like its parent compound risperidone, functions as an inverse agonist at 5-HT2A receptor 15. Paliperidone also acts as an antagonist of alpha-1 and alpha-2 adrenergic receptors as well as H1 histamine receptors. Food is known to increase the absorption of Invega type ER OROS prolonged-release tablets. Food increased exposure of paliperidone by up to 50-60%; however, half-life was not significantly affected. The effect was probably due to a delay in the transit of the ER OROS formulation in the upper part of the GI tract, resulting in increased absorption. Risperidone and its metabolite paliperidone are reduced in efficacy by P-glycoprotein inducers such as St John's wort
=== Phase 1 === 2-Bromo-LSD (bromolysergide; BOL-148; NYPRG-101) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – cluster headache, migraine JS-010 – monoclonal antibody against calcitonin gene-related peptide (CGRP) – migraine [30] Meloxicam – COX inhibitor/NSAID – migraine [31]
Amat-Mamu was a nadītu, a priestess to the god Shamash. She was the daughter of Sin-ilum (also transcribed as Sîn-ilum or Sin-ili). Sin-ilum was the son of Sin-tajjār, who in turn was the son of Akšāja. Amat-Mamu had a cousin, an aunt, and a great aunt who were all nadītus as well. Nadītus were sometimes allowed to choose their own heirs, including potential heirs outside of their own families. Such an option was allowed to the nadītu Belessunu, daughter of Mannium, as part of the terms of her own adoption as the heir of her aunt Naramtum, and Belessunu adopted Amat-Mamu as her heir. Amat-Mamu inherited four fields totaling 46 acres: a five-acre field and a 20 acre field in the Pzur-Ilaba district, a nine-acre field in the Akbarum district, and a 12 acre field in the Pahuşu district. She also inherited two plots of land: one and one-third sar of partially developed land in the cloister and six sar of undeveloped land of Sippar-rabum. Amat-Mamu inherited three slaves from Belessunu: Ana-pani-Šamaš-nadi, Sin-mašmaš, and Sin-mašmaš's brother. Also inherited were a house, two copper pots, and two axes. Amat-Mamu was given the deeds, or "mother tablets", entitling her to Belessunu's property. Per the terms of the agreement, Amat-Mamu was required to pay Belessunu's debts and provide for her while she lived. The debt totaled two-thirds mina, six shekels of silver. To provide for Belessunu, Amat-Mamu was required to provide Belessunu with six gurs of grain, 12 minas of wool, 24 liters of oil, six feasts, 20 liters of flour, and two pieces of meat each year.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.